The role of glucuronidation in drug resistance
- 1 March 2016
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 159, 35-55
Abstract
No abstract availableKeywords
Funding Information
- National Science Center, Poland (OPUS 5, 2013/09/B/NZ3/00003)
This publication has 222 references indexed in Scilit:
- Compartment-Specific Gene Regulation of the CAR Inducer Efavirenz In VivoClinical Pharmacology & Therapeutics, 2012
- Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patientsJournal of Antimicrobial Chemotherapy, 2011
- Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CARAdvanced Drug Delivery Reviews, 2010
- Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumoursEuropean Journal of Cancer, 2010
- Redox Regulation of Multidrug Resistance in Cancer Chemotherapy: Molecular Mechanisms and Therapeutic OpportunitiesAntioxidants & Redox Signaling, 2009
- Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissuesSteroids, 2008
- Novel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target geneSteroids, 2007
- Phenylalanine90 and phenylalanine93 are crucial amino acids within the estrogen binding site of the human UDP-glucuronosyltransferase 1A10Steroids, 2007
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002